Market capitalization | $483.38m |
Enterprise Value | $464.52m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.96 |
P/S ratio (TTM) P/S ratio | 14.52 |
P/B ratio (TTM) P/B ratio | 7.09 |
Revenue growth (TTM) Revenue growth | 137.42% |
Revenue (TTM) Revenue | $33.28m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
6 Analysts have issued a MeiraGTx Holdings plc forecast:
6 Analysts have issued a MeiraGTx Holdings plc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 33 33 |
137%
137%
|
|
Gross Profit | -3.34 -3.34 |
1,252%
1,252%
|
|
EBITDA | -151 -151 |
23%
23%
|
EBIT (Operating Income) EBIT | -164 -164 |
20%
20%
|
Net Profit | -148 -148 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Head office | Cayman Islands |
CEO | Alexandria Forbes |
Employees | 381 |
Founded | 2015 |
Website | www.meiragtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.